am 251 has been researched along with Allodynia in 31 studies
AM 251: an analog of SR141716A; structure given in first source
AM-251 : A carbohydrazide obtained by formal condensation of the carboxy group of 1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-1H-pyrazole-3-carboxylic acid with the amino group of 1-aminopiperidine. An antagonist at the CB1 cannabinoid receptor.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Spinal glial activation has been implicated in sustained morphine-mediated paradoxical pain sensitization." | 7.78 | Repeated morphine treatment-mediated hyperalgesia, allodynia and spinal glial activation are blocked by co-administration of a selective cannabinoid receptor type-2 agonist. ( Keresztes, A; Largent-Milnes, TM; Ren, J; Roeske, WR; Tumati, S; Vanderah, TW; Varga, EV, 2012) |
| ") suppressed the maintenance of mechanical and cold allodynia in the cisplatin and paclitaxel models." | 7.78 | The maintenance of cisplatin- and paclitaxel-induced mechanical and cold allodynia is suppressed by cannabinoid CB₂ receptor activation and independent of CXCR4 signaling in models of chemotherapy-induced peripheral neuropathy. ( Deng, L; Guindon, J; Hohmann, AG; Makriyannis, A; Thakur, GA; Vemuri, VK; White, FA, 2012) |
| "Seven days of treatment with CBD reduced mechanical allodynia, decreased anxiety-like behavior, and normalized 5-HT activity." | 5.51 | Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain. ( Aboud, M; Comai, S; De Gregorio, D; Enns, J; Gobbi, G; Lopez-Canul, M; Maione, S; McLaughlin, RJ; Ochoa-Sanchez, R; Posa, L, 2019) |
| "N-arachidonoylserotonin (AA-5-HT, 1a) is an inhibitor of fatty acid amide hydrolase (FAAH) that acts also as an antagonist of transient receptor potential vanilloid-type 1 (TRPV1) channels and is analgesic in rodents." | 5.34 | New N-arachidonoylserotonin analogues with potential "dual" mechanism of action against pain. ( Cascio, MG; de Novellis, V; De Petrocellis, L; Di Marzo, V; Maione, S; Morera, E; Nalli, M; Ortar, G; Rossi, F; Schiano-Moriello, A; Woodward, DF, 2007) |
| "The pharmacological inhibition of anandamide (AEA) hydrolysis by fatty acid amide hydrolase (FAAH) attenuates pain in animal models of osteoarthritis (OA) but has failed in clinical trials." | 3.81 | A multi-target approach for pain treatment: dual inhibition of fatty acid amide hydrolase and TRPV1 in a rat model of osteoarthritis. ( Binkowski, M; Czaja, M; Di Marzo, V; Kolosowska, N; Makuch, W; Malek, N; Morera, E; Mrugala, M; Przewlocka, B; Starowicz, K, 2015) |
| "Spinal glial activation has been implicated in sustained morphine-mediated paradoxical pain sensitization." | 3.78 | Repeated morphine treatment-mediated hyperalgesia, allodynia and spinal glial activation are blocked by co-administration of a selective cannabinoid receptor type-2 agonist. ( Keresztes, A; Largent-Milnes, TM; Ren, J; Roeske, WR; Tumati, S; Vanderah, TW; Varga, EV, 2012) |
| ") suppressed the maintenance of mechanical and cold allodynia in the cisplatin and paclitaxel models." | 3.78 | The maintenance of cisplatin- and paclitaxel-induced mechanical and cold allodynia is suppressed by cannabinoid CB₂ receptor activation and independent of CXCR4 signaling in models of chemotherapy-induced peripheral neuropathy. ( Deng, L; Guindon, J; Hohmann, AG; Makriyannis, A; Thakur, GA; Vemuri, VK; White, FA, 2012) |
| "This study shows that electroacupuncture increases the anandamide level in inflammatory skin tissues, and CB2 receptors contribute to the analgesic effect of electroacupuncture in a rat model of inflammatory pain." | 3.75 | Endogenous anandamide and cannabinoid receptor-2 contribute to electroacupuncture analgesia in rats. ( Chen, L; Li, F; Li, M; Li, YH; Pan, HL; Qiu, Y; Shi, J; Wang, L; Zhang, J, 2009) |
| "AM404 attenuated mechanical and cold hyperalgesia with minimal effects on motor coordination." | 1.62 | Inhibitory effect of intrathecally administered AM404, an endocannabinoid reuptake inhibitor, on neuropathic pain in a rat chronic constriction injury model. ( Hara, K; Haranishi, Y; Terada, T, 2021) |
| "Pain is a prevalent PD's non-motor symptom with a higher prevalence of analgesic drugs prescription for patients." | 1.56 | Cannabidiol increases the nociceptive threshold in a preclinical model of Parkinson's disease. ( Bortolanza, M; Crivelaro do Nascimento, G; Del Bel, EA; Ferrari, DP; Ferreira-Junior, NC; Guimaraes, FS, 2020) |
| "Seven days of treatment with CBD reduced mechanical allodynia, decreased anxiety-like behavior, and normalized 5-HT activity." | 1.51 | Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain. ( Aboud, M; Comai, S; De Gregorio, D; Enns, J; Gobbi, G; Lopez-Canul, M; Maione, S; McLaughlin, RJ; Ochoa-Sanchez, R; Posa, L, 2019) |
| "Paclitaxel produced mechanical and cold allodynia without altering nestlet shredding or marble burying behaviors." | 1.48 | Brain-Permeant and -Impermeant Inhibitors of Fatty Acid Amide Hydrolase Synergize with the Opioid Analgesic Morphine to Suppress Chemotherapy-Induced Neuropathic Nociception Without Enhancing Effects of Morphine on Gastrointestinal Transit. ( Hohmann, AG; Iyer, V; Makriyannis, A; Saberi, SA; Slivicki, RA; Vemuri, VK, 2018) |
| "MCS reversed mechanical hyperalgesia, inhibited astrocyte and microglial activity, decreased proinflammatory cytokine staining, enhanced CB2 staining, and downregulated P2X4 receptors in the DHSC ipsilateral to sciatic injury." | 1.42 | The spinal anti-inflammatory mechanism of motor cortex stimulation: cause of success and refractoriness in neuropathic pain? ( Fonoff, ET; Lopes, PS; Pagano, RL; Silva, GD, 2015) |
| "Mechanical allodynia and thermal hyperalgesia were evaluated in 436 male C57BL/6, cnr1KO and cnr2KO mice in the presence or absence of cannabinoid CB₁ (AM251) or CB₂ (AM630) receptor antagonists in a mouse model of neuropathic pain." | 1.40 | Endocannabinoids decrease neuropathic pain-related behavior in mice through the activation of one or both peripheral CB₁ and CB₂ receptors. ( Beaulieu, P; Bouchard, JF; Charron, S; Desroches, J, 2014) |
| "Mechanical allodynia and thermal hyperalgesia were tested on ventral paw for 14 days." | 1.40 | Cannabinoid receptor type 1 antagonist, AM251, attenuates mechanical allodynia and thermal hyperalgesia after burn injury. ( Iwasaki, H; Mao, J; Martyn, JA; Murata, E; Poon, KY; Ueda, M; Wang, S, 2014) |
| "To induce hyperalgesia, rat paws were treated with intraplantar prostaglandin E2 (PGE2, 2μg)." | 1.39 | Probable involvement of Ca(2+)-activated Cl(-) channels (CaCCs) in the activation of CB1 cannabinoid receptors. ( Duarte, ID; Pacheco, Dda F; Romero, TR, 2013) |
| "However, RVM inactivation blocked the hyperalgesia produced upon removal from the EPM." | 1.38 | Contribution of the rostral ventromedial medulla to post-anxiety induced hyperalgesia. ( Cornélio, AM; Morgan, MM; Nunes-de-Souza, RL, 2012) |
| "The effects of NADA and EM on thermal hyperalgesia were evaluated in rats with a unilateral hind paw carrageenan-induced inflammation." | 1.37 | The antinociceptive potency of N-arachidonoyl-dopamine (NADA) and its interaction with endomorphin-1 at the spinal level. ( Benedek, G; Farkas, I; Horvath, G; Tuboly, G, 2011) |
| "Thermal hyperalgesia was significantly ameliorated in a dose-dependent manner with systemically administered WIN." | 1.36 | Cannabinoid subtype-2 receptors modulate the antihyperalgesic effect of WIN 55,212-2 in rats with neuropathic spinal cord injury pain. ( Ahmed, MM; Allcock, B; Gerovac, TA; McChesney, S; Miranpuri, GS; Patel, AU; Rajpal, S; Resnick, DK; Sweeney, C; Tilghman, JI, 2010) |
| "The NAGly induced anti-allodynia was dose dependent and, unlike HU-210, was unaffected by the cannabinoid CB(1) and CB(2) receptor antagonists, AM251 and SR144528 (30 nmol)." | 1.35 | Actions of N-arachidonyl-glycine in a rat neuropathic pain model. ( Mitchell, VA; Vaughan, CW; Vuong, LA, 2008) |
| "N-arachidonoylserotonin (AA-5-HT, 1a) is an inhibitor of fatty acid amide hydrolase (FAAH) that acts also as an antagonist of transient receptor potential vanilloid-type 1 (TRPV1) channels and is analgesic in rodents." | 1.34 | New N-arachidonoylserotonin analogues with potential "dual" mechanism of action against pain. ( Cascio, MG; de Novellis, V; De Petrocellis, L; Di Marzo, V; Maione, S; Morera, E; Nalli, M; Ortar, G; Rossi, F; Schiano-Moriello, A; Woodward, DF, 2007) |
| "Mechanical allodynia and thermal hyperalgesia were evaluated in 46 rats allocated to receive: (1) Vehicle (before surgery)-Vehicle (after surgery); (2) Vehicle-WIN55,212-2; (3) WIN55,212-2-Vehicle; (4) WIN55,212-2-WIN55,212-2; (5) AM251+vehicle; (6) AM251+WIN55,212-2; (7) AM630+vehicle; (8) AM630+WIN55,212-2; (9) Sham receiving vehicle; and (10) Sham receiving WIN55,212-2." | 1.34 | Pre-emptive antinociceptive effects of a synthetic cannabinoid in a model of neuropathic pain. ( Beaulieu, P; Dani, M; Desroches, J; Guindon, J, 2007) |
| "Both mechanical allodynia and thermal hyperalgesia are seen both ipsilateral and contralateral to the side of nerve injury, but is significantly more severe ipsilaterally." | 1.34 | The synthetic cannabinoids attenuate allodynia and hyperalgesia in a rat model of trigeminal neuropathic pain. ( Hsu, KS; Huang, CC; Liang, YC, 2007) |
| "Paracetamol dose-dependently decreased mechanical allodynia and lowered nociceptive scores associated with hyperalgesia testing." | 1.34 | The local antinociceptive effects of paracetamol in neuropathic pain are mediated by cannabinoid receptors. ( Beaulieu, P; Dani, M; Guindon, J; Lambert, C, 2007) |
| "WIN 55,212-2 attenuated both heat and mechanical hyperalgesia dose-dependently." | 1.32 | Activation of peripheral cannabinoid receptors attenuates cutaneous hyperalgesia produced by a heat injury. ( Johanek, LM; Simone, DA, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (29.03) | 29.6817 |
| 2010's | 20 (64.52) | 24.3611 |
| 2020's | 2 (6.45) | 2.80 |
| Authors | Studies |
|---|---|
| Ortar, G | 1 |
| Cascio, MG | 1 |
| De Petrocellis, L | 1 |
| Morera, E | 2 |
| Rossi, F | 1 |
| Schiano-Moriello, A | 1 |
| Nalli, M | 1 |
| de Novellis, V | 1 |
| Woodward, DF | 1 |
| Maione, S | 2 |
| Di Marzo, V | 2 |
| Crivelaro do Nascimento, G | 1 |
| Ferrari, DP | 1 |
| Guimaraes, FS | 1 |
| Del Bel, EA | 1 |
| Bortolanza, M | 1 |
| Ferreira-Junior, NC | 1 |
| Haranishi, Y | 1 |
| Hara, K | 1 |
| Terada, T | 1 |
| Segat, GC | 1 |
| Manjavachi, MN | 1 |
| Matias, DO | 1 |
| Passos, GF | 1 |
| Freitas, CS | 1 |
| Costa, R | 1 |
| Calixto, JB | 1 |
| Giorno, TBS | 1 |
| Moreira, IGDS | 1 |
| Rezende, CM | 1 |
| Fernandes, PD | 1 |
| De Gregorio, D | 1 |
| McLaughlin, RJ | 1 |
| Posa, L | 1 |
| Ochoa-Sanchez, R | 1 |
| Enns, J | 1 |
| Lopez-Canul, M | 1 |
| Aboud, M | 1 |
| Comai, S | 1 |
| Gobbi, G | 1 |
| Slivicki, RA | 2 |
| Saberi, SA | 1 |
| Iyer, V | 1 |
| Vemuri, VK | 2 |
| Makriyannis, A | 2 |
| Hohmann, AG | 3 |
| Freitas, RL | 1 |
| Salgado-Rohner, CJ | 1 |
| Hallak, JE | 1 |
| Crippa, JA | 1 |
| Coimbra, NC | 1 |
| Duncan, M | 1 |
| Galic, MA | 1 |
| Wang, A | 1 |
| Chambers, AP | 1 |
| McCafferty, DM | 1 |
| McKay, DM | 1 |
| Sharkey, KA | 1 |
| Pittman, QJ | 1 |
| Desroches, J | 2 |
| Charron, S | 1 |
| Bouchard, JF | 1 |
| Beaulieu, P | 3 |
| Ueda, M | 1 |
| Iwasaki, H | 1 |
| Wang, S | 1 |
| Murata, E | 1 |
| Poon, KY | 1 |
| Mao, J | 1 |
| Martyn, JA | 1 |
| Krustev, E | 1 |
| Reid, A | 1 |
| McDougall, JJ | 1 |
| Silva, GD | 1 |
| Lopes, PS | 1 |
| Fonoff, ET | 1 |
| Pagano, RL | 1 |
| Malek, N | 1 |
| Mrugala, M | 1 |
| Makuch, W | 1 |
| Kolosowska, N | 1 |
| Przewlocka, B | 1 |
| Binkowski, M | 1 |
| Czaja, M | 1 |
| Starowicz, K | 1 |
| Parvathy, SS | 1 |
| Masocha, W | 1 |
| Carey, LM | 1 |
| Leishman, E | 1 |
| Cornett, B | 1 |
| Mackie, K | 1 |
| Bradshaw, H | 1 |
| Chen, L | 1 |
| Zhang, J | 1 |
| Li, F | 1 |
| Qiu, Y | 1 |
| Wang, L | 1 |
| Li, YH | 1 |
| Shi, J | 1 |
| Pan, HL | 1 |
| Li, M | 1 |
| Ahmed, MM | 1 |
| Rajpal, S | 1 |
| Sweeney, C | 1 |
| Gerovac, TA | 1 |
| Allcock, B | 1 |
| McChesney, S | 1 |
| Patel, AU | 1 |
| Tilghman, JI | 1 |
| Miranpuri, GS | 1 |
| Resnick, DK | 1 |
| Farkas, I | 1 |
| Tuboly, G | 1 |
| Benedek, G | 1 |
| Horvath, G | 1 |
| Tumati, S | 1 |
| Largent-Milnes, TM | 1 |
| Keresztes, A | 1 |
| Ren, J | 1 |
| Roeske, WR | 1 |
| Vanderah, TW | 1 |
| Varga, EV | 1 |
| Escobar, W | 1 |
| Ramirez, K | 1 |
| Avila, C | 1 |
| Limongi, R | 1 |
| Vanegas, H | 1 |
| Vazquez, E | 1 |
| Cornélio, AM | 1 |
| Nunes-de-Souza, RL | 1 |
| Morgan, MM | 1 |
| Deng, L | 1 |
| Guindon, J | 3 |
| Thakur, GA | 1 |
| White, FA | 1 |
| Romero, TR | 1 |
| Pacheco, Dda F | 1 |
| Duarte, ID | 2 |
| Johanek, LM | 1 |
| Simone, DA | 1 |
| Liu, C | 1 |
| Walker, JM | 1 |
| Dani, M | 2 |
| Liang, YC | 1 |
| Huang, CC | 1 |
| Hsu, KS | 1 |
| Vuong, LA | 1 |
| Mitchell, VA | 1 |
| Vaughan, CW | 1 |
| Lambert, C | 1 |
| da Fonseca Pacheco, D | 1 |
| Klein, A | 1 |
| de Castro Perez, A | 1 |
| da Fonseca Pacheco, CM | 1 |
| de Francischi, JN | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Dose Controlled Diabetic Neuropathic Pain Study Using Non-Intoxicating Cannabidiol in a Rapidly Dissolvable Sublingual Tablet[NCT04088929] | Phase 2 | 32 participants (Actual) | Interventional | 2019-09-30 | Completed | ||
| A Randomized, Double-Blind, Placebo-Controlled Trial Using Cannabidiol for the Treatment of Painful Diabetic Peripheral Neuropathy of the Feet[NCT04679545] | Phase 2 | 50 participants (Anticipated) | Interventional | 2020-12-10 | Recruiting | ||
| Cannabinoids and an Anti-inflammatory Diet for the Treatment of Neuropathic Pain After Spinal Cord Injury[NCT04057456] | Phase 3 | 140 participants (Anticipated) | Interventional | 2023-03-01 | Recruiting | ||
| A Randomized, Double-Blind, Placebo-Controlled Trial Using Cannabidiol and Palmitoylethanolamide for the Treatment of Painful Diabetic Peripheral Neuropathy of the Feet[NCT05766969] | Phase 1/Phase 2 | 52 participants (Anticipated) | Interventional | 2023-06-05 | Not yet recruiting | ||
| Osteoarthritis of the Knee Pain Study Using CBD and THC in Rapidly Dissolvable Sublingual Tablet[NCT04195269] | Phase 2 | 30 participants (Anticipated) | Interventional | 2020-04-20 | Recruiting | ||
| Stress and Opioid Misuse Risk: The Role of Endogenous Opioid and Endocannabinoid Mechanisms[NCT05142267] | 120 participants (Anticipated) | Interventional | 2022-03-02 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
31 other studies available for am 251 and Allodynia
| Article | Year |
|---|---|
New N-arachidonoylserotonin analogues with potential "dual" mechanism of action against pain.
Topics: Amidohydrolases; Analgesics; Animals; Arachidonic Acids; Biphenyl Compounds; Brain; Calcium; Carbama | 2007 |
Cannabidiol increases the nociceptive threshold in a preclinical model of Parkinson's disease.
Topics: Amidohydrolases; Analgesics; Animals; Benzamides; Brain; Cannabidiol; Capsaicin; Carbamates; Celecox | 2020 |
Inhibitory effect of intrathecally administered AM404, an endocannabinoid reuptake inhibitor, on neuropathic pain in a rat chronic constriction injury model.
Topics: Animals; Arachidonic Acids; Capsaicin; Constriction; Disease Models, Animal; Endocannabinoids; Hyper | 2021 |
Antiallodynic effect of β-caryophyllene on paclitaxel-induced peripheral neuropathy in mice.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents, Phyto | 2017 |
New
Topics: Analgesics; Animals; Behavior, Animal; Capsaicin; Coffee; Disease Models, Animal; Female; Formaldehy | 2018 |
Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain.
Topics: Action Potentials; Animals; Anxiety; Cannabidiol; Capsaicin; Disease Models, Animal; Exploratory Beh | 2019 |
Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain.
Topics: Action Potentials; Animals; Anxiety; Cannabidiol; Capsaicin; Disease Models, Animal; Exploratory Beh | 2019 |
Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain.
Topics: Action Potentials; Animals; Anxiety; Cannabidiol; Capsaicin; Disease Models, Animal; Exploratory Beh | 2019 |
Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain.
Topics: Action Potentials; Animals; Anxiety; Cannabidiol; Capsaicin; Disease Models, Animal; Exploratory Beh | 2019 |
Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain.
Topics: Action Potentials; Animals; Anxiety; Cannabidiol; Capsaicin; Disease Models, Animal; Exploratory Beh | 2019 |
Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain.
Topics: Action Potentials; Animals; Anxiety; Cannabidiol; Capsaicin; Disease Models, Animal; Exploratory Beh | 2019 |
Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain.
Topics: Action Potentials; Animals; Anxiety; Cannabidiol; Capsaicin; Disease Models, Animal; Exploratory Beh | 2019 |
Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain.
Topics: Action Potentials; Animals; Anxiety; Cannabidiol; Capsaicin; Disease Models, Animal; Exploratory Beh | 2019 |
Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain.
Topics: Action Potentials; Animals; Anxiety; Cannabidiol; Capsaicin; Disease Models, Animal; Exploratory Beh | 2019 |
Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain.
Topics: Action Potentials; Animals; Anxiety; Cannabidiol; Capsaicin; Disease Models, Animal; Exploratory Beh | 2019 |
Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain.
Topics: Action Potentials; Animals; Anxiety; Cannabidiol; Capsaicin; Disease Models, Animal; Exploratory Beh | 2019 |
Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain.
Topics: Action Potentials; Animals; Anxiety; Cannabidiol; Capsaicin; Disease Models, Animal; Exploratory Beh | 2019 |
Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain.
Topics: Action Potentials; Animals; Anxiety; Cannabidiol; Capsaicin; Disease Models, Animal; Exploratory Beh | 2019 |
Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain.
Topics: Action Potentials; Animals; Anxiety; Cannabidiol; Capsaicin; Disease Models, Animal; Exploratory Beh | 2019 |
Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain.
Topics: Action Potentials; Animals; Anxiety; Cannabidiol; Capsaicin; Disease Models, Animal; Exploratory Beh | 2019 |
Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain.
Topics: Action Potentials; Animals; Anxiety; Cannabidiol; Capsaicin; Disease Models, Animal; Exploratory Beh | 2019 |
Brain-Permeant and -Impermeant Inhibitors of Fatty Acid Amide Hydrolase Synergize with the Opioid Analgesic Morphine to Suppress Chemotherapy-Induced Neuropathic Nociception Without Enhancing Effects of Morphine on Gastrointestinal Transit.
Topics: Amidohydrolases; Analgesics, Opioid; Animals; Antineoplastic Agents; Arachidonic Acids; Benzamides; | 2018 |
Involvement of prelimbic medial prefrontal cortex in panic-like elaborated defensive behaviour and innate fear-induced antinociception elicited by GABAA receptor blockade in the dorsomedial and ventromedial hypothalamic nuclei: role of the endocannabinoid
Topics: Analysis of Variance; Animals; Bicuculline; Defense Mechanisms; Disease Models, Animal; Dose-Respons | 2013 |
Cannabinoid 1 receptors are critical for the innate immune response to TLR4 stimulation.
Topics: Animals; Body Temperature; Cytokines; Data Interpretation, Statistical; Fever; Hyperalgesia; Immunit | 2013 |
Endocannabinoids decrease neuropathic pain-related behavior in mice through the activation of one or both peripheral CB₁ and CB₂ receptors.
Topics: Animals; Arachidonic Acids; Behavior, Animal; Endocannabinoids; Glycerides; Hyperalgesia; Male; Mice | 2014 |
Cannabinoid receptor type 1 antagonist, AM251, attenuates mechanical allodynia and thermal hyperalgesia after burn injury.
Topics: Aging; Analgesics, Non-Narcotic; Animals; Burns; Hyperalgesia; Injections, Spinal; Male; Neuroglia; | 2014 |
Tapping into the endocannabinoid system to ameliorate acute inflammatory flares and associated pain in mouse knee joints.
Topics: Acute Disease; Amidohydrolases; Animals; Arthralgia; Benzamides; Carbamates; Carrageenan; Endocannab | 2014 |
The spinal anti-inflammatory mechanism of motor cortex stimulation: cause of success and refractoriness in neuropathic pain?
Topics: Analysis of Variance; Animals; Anti-Inflammatory Agents; Calcium-Binding Proteins; Cytokines; Deep B | 2015 |
A multi-target approach for pain treatment: dual inhibition of fatty acid amide hydrolase and TRPV1 in a rat model of osteoarthritis.
Topics: Activating Transcription Factor 3; Amidohydrolases; Anilides; Animals; Arachidonic Acids; Benzamides | 2015 |
Coadministration of indomethacin and minocycline attenuates established paclitaxel-induced neuropathic thermal hyperalgesia: Involvement of cannabinoid CB1 receptors.
Topics: Animals; Female; Hyperalgesia; Indomethacin; Male; Mice; Mice, Inbred BALB C; Minocycline; Paclitaxe | 2015 |
A pro-nociceptive phenotype unmasked in mice lacking fatty-acid amide hydrolase.
Topics: Acrylamides; Amidohydrolases; Analgesia; Animals; Arachidonic Acid; Bridged Bicyclo Compounds, Heter | 2016 |
Endogenous anandamide and cannabinoid receptor-2 contribute to electroacupuncture analgesia in rats.
Topics: Animals; Arachidonic Acids; Chromatography, High Pressure Liquid; Electroacupuncture; Endocannabinoi | 2009 |
Cannabinoid subtype-2 receptors modulate the antihyperalgesic effect of WIN 55,212-2 in rats with neuropathic spinal cord injury pain.
Topics: Analgesics; Analysis of Variance; Animals; Benzoxazines; Dose-Response Relationship, Drug; Hot Tempe | 2010 |
The antinociceptive potency of N-arachidonoyl-dopamine (NADA) and its interaction with endomorphin-1 at the spinal level.
Topics: Acrylamides; Analgesics; Animals; Arachidonic Acids; Area Under Curve; Bridged Bicyclo Compounds, He | 2011 |
Repeated morphine treatment-mediated hyperalgesia, allodynia and spinal glial activation are blocked by co-administration of a selective cannabinoid receptor type-2 agonist.
Topics: Analgesics; Analgesics, Opioid; Animals; Cannabinoids; Hyperalgesia; Indoles; Inflammation; Interleu | 2012 |
Metamizol, a non-opioid analgesic, acts via endocannabinoids in the PAG-RVM axis during inflammation in rats.
Topics: Action Potentials; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cannabinoid Receptor Modulators | 2012 |
Contribution of the rostral ventromedial medulla to post-anxiety induced hyperalgesia.
Topics: Animals; Anxiety; GABA-A Receptor Agonists; Hyperalgesia; Male; Medulla Oblongata; Muscimol; Pain Me | 2012 |
The maintenance of cisplatin- and paclitaxel-induced mechanical and cold allodynia is suppressed by cannabinoid CB₂ receptor activation and independent of CXCR4 signaling in models of chemotherapy-induced peripheral neuropathy.
Topics: Animals; Benzylamines; Chromones; Cisplatin; Cryopyrin-Associated Periodic Syndromes; Cyclams; Disea | 2012 |
Probable involvement of Ca(2+)-activated Cl(-) channels (CaCCs) in the activation of CB1 cannabinoid receptors.
Topics: Amides; Analysis of Variance; Animals; Arachidonic Acids; Calcium Channel Blockers; Cannabinoid Rece | 2013 |
Activation of peripheral cannabinoid receptors attenuates cutaneous hyperalgesia produced by a heat injury.
Topics: Animals; Benzoxazines; Burns; Cannabinoid Receptor Agonists; Cannabinoid Receptor Antagonists; Disea | 2004 |
Effects of a cannabinoid agonist on spinal nociceptive neurons in a rodent model of neuropathic pain.
Topics: Analgesics; Animals; Behavior, Animal; Benzoxazines; Camphanes; Cannabinoid Receptor Agonists; Canna | 2006 |
Pre-emptive antinociceptive effects of a synthetic cannabinoid in a model of neuropathic pain.
Topics: Analgesics; Animals; Benzoxazines; Cannabinoids; Hyperalgesia; Indoles; Male; Morpholines; Naphthale | 2007 |
The synthetic cannabinoids attenuate allodynia and hyperalgesia in a rat model of trigeminal neuropathic pain.
Topics: Analgesics; Analysis of Variance; Animals; Benzoxazines; Cannabinoids; Disease Models, Animal; Dose- | 2007 |
Actions of N-arachidonyl-glycine in a rat neuropathic pain model.
Topics: Analgesics; Animals; Arachidonic Acids; Area Under Curve; Camphanes; Disease Models, Animal; Dose-Re | 2008 |
The local antinociceptive effects of paracetamol in neuropathic pain are mediated by cannabinoid receptors.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Animals; Arachidonic Acids; Cannabinoid Receptor Antagonist | 2007 |
The mu-opioid receptor agonist morphine, but not agonists at delta- or kappa-opioid receptors, induces peripheral antinociception mediated by cannabinoid receptors.
Topics: Amidohydrolases; Analgesics, Opioid; Animals; Arachidonic Acids; Benzamides; Benzomorphans; Cannabin | 2008 |